News

Cascade Prodrug Expands Board with Experienced Leaders in Oncology

Cascade Prodrug Expands Board with Experienced Leaders in Oncology

Cascade Prodrug Strengthens Board of Directors

Cascade Prodrug, Inc. is pleased to announce the addition of two esteemed professionals, Manuel (Manny) Litchman, M.D. and Andres Gutierrez, M.D., Ph.D., to its Board of Directors. This strategic move comes as the company enhances its commitment to developing innovative hypoxia-activated therapies for oncology. With their extensive backgrounds, Dr. Litchman and Dr. Gutierrez are well-positioned to guide Cascade into its next phase of growth.

Experience of New Board Members

Dr. Litchman, who has been leading Mustang Bio as President and CEO since April 2017, brings over 30 years of biopharmaceutical experience. His notable career includes previous leadership roles at Arvinas, Inc. and Novartis Pharmaceuticals, where he was instrumental in notable projects including CTL019 (now Kymriah). His vast expertise encompasses areas such as drug development, corporate financing, and the ever-important experience in clinical operations.

Educational Excellence

Dr. Litchman earned his medical degree from the prestigious Yale University School of Medicine. Following this, he completed a rigorous residency in internal medicine and a fellowship in hematology-oncology at New York-Presbyterian Hospital and Weill Cornell Medical Center, laying a strong foundation for his future successes in the field.

The Contributions of Dr. Gutierrez

Joining him is Dr. Andres Gutierrez, who is highly regarded for his extensive expertise spanning over two decades in oncology. His career highlights include significant roles in leading clinical developments and managing large teams across various functions like regulatory affairs, strategy, and fundraising. Previously, he served as Chief Medical Officer for several biotech companies including Ayala, Advaxis, and Oncolytics Biotech.

A Broad Spectrum of Knowledge

Dr. Gutierrez holds both M.D. and Ph.D. degrees and completed his internal medicine residency in Mexico, followed by an esteemed fellowship in Clinical Oncology Research at Hammersmith Hospital in London. His insights into drug efficacy and patient outcomes will be invaluable as Cascade Prodrug seeks to advance its clinical initiatives.

A Statement from Cascade's Leadership

Reacting to the new appointments, Allan Cochrane, President and Co-Founder of Cascade Prodrug, expressed his enthusiasm stating, "Manny and Andres bring a wealth of knowledge in oncology and drug development to our board. Their experience will be critical as we progress with our lead compound CPD100Li into clinical trials." The excitement surrounding their expertise highlights the strategic decisions Cascade is making to ensure effective leadership in its groundbreaking projects.

Looking Forward: The Future of Cascade Prodrug

Dr. Litchman expressed his honor in joining the board at a transformative time for Cascade. He acknowledged the potential of the company's innovative approach to oncology drug delivery and his eagerness to collaborate with existing board members and leadership to accelerate the development of CPD100Li, which is poised for a Phase 1 clinical trial.

Welcoming a New Era

Dr. Gutierrez also shared his anticipation for what lies ahead, stating, "This opportunity aligns perfectly with my commitment to advancing cancer treatments. I look forward to collaborating with Dr. Litchman and the talented team at Cascade to make a significant impact in the field of oncology." Their combined vision and leadership are set to propel Cascade to new heights.

About Cascade Prodrug, Inc.

Cascade Prodrug, Inc. is dedicated to developing hypoxia-activated therapeutics that target one of the most common characteristics of tumor microenvironments. The company's lead candidate, CPD100Li, has shown promising preclinical efficacy across multiple cancer types, including pancreatic, lung, and colon cancers, either alone or in combination with various treatment methodologies.

Contact Information for Cascade Prodrug

For further inquiries or details regarding their innovative research and development, you can reach out to:

Cascade Prodrug, Inc.
Allan Cochrane
President & Co-Founder
Email: allan@cascadeprodrug.com

Eric Malek
Chief Business Officer
Email: eric@cascadeprodrug.com

Frequently Asked Questions

What is the mission of Cascade Prodrug, Inc.?

Cascade Prodrug focuses on developing hypoxia-activated therapies aimed at improving cancer treatments and patient outcomes.

Who are the newly appointed board members?

The new board members are Manuel Litchman, M.D. and Andres Gutierrez, M.D., Ph.D., who bring a wealth of experience in oncology and drug development.

What is the role of CPD100Li?

CPD100Li, Cascade's lead compound, is designed to be highly effective against various cancers by targeting the unique aspects of the tumor microenvironment.

How does Cascade Prodrug aim to advance its therapies?

The company emphasizes innovation and collaboration within its leadership team to expedite the clinical trial process and bring treatments to market.

What previous roles did the new board members hold?

Dr. Litchman was previously the CEO of Mustang Bio, and Dr. Gutierrez has held CMO roles at several biotech firms, leading significant oncology developments.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Google Search Data Sharing Faces a Privacy Reality Check

Updated Category News Views 58

Search queries are messy little confessions, and that is exactly why this case deserves more than a bureaucratic shrug. Woodway Assurance's independent assessment says Google's search-query data could be treated as anonymized for sharing under the Digital Markets Act, but only if the European Commission tightens parts of its July 2026 framework. That is not a clean bill...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 194

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 183

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
FULC, DSGR and OPCH Deals Draw Fresh Shareholder Scrutiny

Updated Category News Views 112

Three proposed transactions have drawn the kind of legal glare that makes shareholders sit up and check the fine print twice. On November 18, 2026, Halper Sadeh LLC said it was investigating deals involving Fulcrum Therapeutics, Distribution Solutions Group, and Option Care Health for possible federal securities-law violations or fiduciary-duty breaches. That is not a...

Continue Reading
MacDill Mold Case Puts Privatized Housing on Notice

Updated Category News Views 109

Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...

Continue Reading
Hisense Year-End Push Tests Its Connected-Home Pitch

Updated Category News Views 11

A 300-inch picture is one heck of a way to sell a refrigerator. Hisense is rolling out year-end offers across the Middle East and Africa that stitch together its premium displays, connected appliances and ConnectLife software under one big household-upgrade pitch. It is glossy stuff, sure, but there is a practical commercial question underneath all the sparkle: can the...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 113

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 296

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 85

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 119

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Launch of RM11, a Game-Changer for Creators

Updated Category News Views 451

Introducing RM11: A New Era for Creators RM11 is an innovative digital platform crafted specifically for creators, prioritizing their needs and ensuring they keep more of their hard-earned money. With a comprehensive payout model allowing creators to retain 90% of earnings, RM11 focuses on fostering a vibrant ecosystem where creators thrive without excessive fees or...

Continue Reading
Tyfast Energy Secures Grant to Enhance Lithium-Ion Battery Tech

Updated Category News Views 174

Tyfast Energy Secures Funding for Advanced Battery Development Tyfast Energy, an innovative battery materials company, has achieved a significant milestone by securing a $100,000 grant aimed at enhancing its development of lithium-ion batteries. This funding, provided by the National Science Foundation's Energy Storage Engine, is expected to expedite the advancement of...

Continue Reading
DMG Blockchain Solutions Sets Stage for AI Growth with MOU

Updated Category News Views 285

DMG Blockchain Solutions Expands into Generative AI DMG Blockchain Solutions Inc. has recently made headlines with its agreement to acquire a 10-megawatt prefabricated data center. This significant advancement positions DMG as a key player in the growing field of Generative Artificial Intelligence (Gen AI). The memorandum of understanding (MOU) signifies a strategic step...

Continue Reading
EPAM Systems Achieves Steady Growth in 2024 Financial Results

Updated Category News Views 205

Financial Overview of EPAM Systems for 2024 EPAM Systems, Inc. (NYSE: EPAM), a premier digital transformation and product engineering company, has reported commendable financial results for the fourth quarter and full year of 2024. The company displayed resilience in its growth amid a changing economic landscape, showcasing a 7.9% increase in revenues year-over-year in...

Continue Reading
Carvana Stock Surges After Bullish Power Inflow Indicator

Updated Category News Views 242

Carvana Stock Gains After Bullish Indicator Carvana Co (NYSE: CVNA) experienced an exciting uptick in its stock price following a noteworthy signal known as the Power Inflow. This indicator, closely monitored by traders focused on order flow analytics, reflects significant shifts in buying momentum, particularly from both institutional and retail investors. The Power...

Continue Reading